Cited by CrossRef (9)

Rojin Park. Attempts to treat patients with hemophilia, the "royal disease". Blood Res 2013;48:235
H. Takedani, J. Hirose, F. Minamoto, M. Kubota, J. Kinkawa, M. Noguchi. Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent. Haemophilia 2016;22
Koji Yada, Natsume Fujitate, Kenichi Ogiwara, Tetsuhiro Soeda, Takehisa Kitazawa, Keiji Nogami. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro. Thrombosis Research 2024;237:37
Ryui Miyashita, Keiko Shinozawa, Eisuke Takami, Koichi Ohkuma, Kagehiro Amano. Effects of low and high factor X concentrations on thrombin generation in vitro. Thrombosis Update 2022;8:100111
Midori Shima. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders. Ann Hematol 2023
Gerard Dolan, Jan Astermark, Cedric Hermans. Recombinant FVIIa in elective non‐orthopaedic surgery of adults with haemophilia and inhibitors: A systematic literature review. Haemophilia 2021;27
Hee Young Ju, Hye Lim Jang, Young Shil Park. The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors. Blood Res 2015;50:173
Matteo Rota, Paolo A. Cortesi, Roberto Crea, Alessandro Gringeri, Lorenzo G. Mantovani. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. 2017;1:2637
Zühre Kaya, Özlem Orhan, Sacit Turanlı, İdil Yenicesu, Ülker Koçak, Türkiz Gürsel. Successful total hip replacement with sequential administration of bypassing agents in an adolescent boy with hemophilia A and high inhibitor titers. 2017;28:419